Atherosclerotic cardiovascular disease is a major burden in old age. As in younger groups, certain lipid profiles are associated with disease; and the benefits of lipid-lowering treatment seem unrelated to age. This is one reason for a rising demand for treatment. Another is the practice of health checks, mainly in primary care. Many individuals who are symptom-free now require decisions on their lipid profiles. Lipid issues are of rising interest in approaches to our ageing and vocal patient population. 0 0 0 0 UL 6.5 6.0 5.5 5.0 REFERENCE RANGES AND WHAT IS AVERAGE In the UK, total and low-density lipoprotein [LDL] cholesterol rises throughout life into old age1, particularly in females (Figure 1 )2,3. Such trends with age are not seen in non-industrialized populations4, and may in large part relate to weight and lifestyle. Triglycerides show lesser age and gender effects; levels of high-density lipoprotein [HDL] cholesterol are higher in females, changing little after pubertyl2; concentrations of total and LDL cholesterol seem to decline at the very end of life' 3. Age-related changes in degree of post-prandial lipaemia5, and in cholesterol synthesis, absorption and turnover6, have been reported but cohort studies point to better survival of individuals with low levels, so a culling effect is at least partly responsible1 ,7. Very high levels of lipoprotein(a), a genetically determined adverse factor that probably interferes with thrombolysis, also seem uncommon in the elderly, but again this could indicate better survival of those with less extreme values8. The tendency of plasma lipids to increase with age and the large scatter around mean values in healthy elderly populations must cast doubt on clinical guidelines and action limits that take no account of age and gender9. All must be seen as guidelines not gospel, to be viewed in a clinical context9 10. For the UK it is noteworthy that a serum cholesterol of 7.0mmol/L, though not ideal by world epidemiological standards, is average for a British woman aged 70 years. -..I O-0 Women 0 Men 30 35 40 45 50 55 60 65 70 75 80 85 Age in years Figure 1 Mean levels of cholesterol in plasma for unselected British adults, in relation to age. Data taken from the UK National Lipid Screening Project for ages 21-59 years2, and the population aged 75 years and above from the town of Melton3
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ABSOLUTE, RELATIVE AND POTENTIAL BENEFIT
The therapeutic window can be narrow in the elderly, thus dosage, response and potential adverse effects must be monitored closely in the early stages2l: the elderly may also be vcry responsive to statins. However, in intervention studies such as the Cholesterol Reduction in Seniors Program (CRISP) trial, treatments have generally been uncomplicated22 and the fear that polypharmacy would cause troublesome drug interactions has been allayed21'22.
Most of the lipid intervention trials have not included elderly people, but three recent statin secondary prevention studies did so. The Scandinavian Simvastatin Survival Study recruited men and women age 35-70 years; the Cholesterol and Recurring Events (CARE) trial men and women age 21-75 years; and the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial men and women age 31-75 years at entry23 25. These trials all showed similar proportional clinical benefit above or below age 55, 60, or 65 years at entry, and in men and w,vomen:
the similar proportional benefit is noteworthy, since absolute risk of events rises with age (although for the oldest old, lipid profiles are not predictive of outcome16).
The three trials also showed similar proportional benefits for non-insulin-dependent diabetics26,27, so there is potential for greater absolute benefits in this age-related disorder with its very high risk of lipid-related vascular complications including death vithin one year of first infarct26'28. Stroke is also age-related and its incidence was likewise reduced in these trials by statins unexpectedly since stroke does not closely correlate with lipid profiles before the event. One possibility is that haemorrhagic stroke might be amplified by control of any lipid-related pro-thrombotic tendency whereas the risk of thrombotic stroke might be reduced. The major lipid trials also suggest that any clinical benefits are not clear-cut until about twro years after entry, so the prescribing clinician may need to consider expectation of otherwise healthy life. The evidence that secondary prevention can be achieved by modification of lipid profiles in the elderly has led to more lipid tests on patients with clinically evident disease. In primary prevention the implications of any abnormal results turned up on lipid screening should be considered in the context of the circumstances causing the test to be done potentially more relevant than risk factors such as family history. In primary prevention the WOSCOPS study29 has shown that there are benefits from treatment of moderate symptomless hypercholesterolaemia at age up to 60 years, but in practice the potential for benefit declines with advancing age. Certainly there is no case for untargeted lipid screening in the oldest old, in the absence of clinically evident atherosclerotic disease. CONCLUSION We now know that the benefits of lipid modification extend to elderly populations, particularly in secondary prevention. Proportional benefit seems independent of age, and the high absolute risk implies substantial potential for reduction of cardiovascular and cerebrovascular events. So far, medical attitudes to risk management in the elderly have been conservative as exemplified by the low use of aspirin after myocardial infarction30. A key issue is whether coronary and other vascular diseases and associated contributory states such as dyslipidaemia are so common in the elderly that they are normal, or so common that management is a very high priority. Perceptions of biological age and presence of other life-threatening disorder will influence management, but beyond that there is a good case for applying guidelines for lipid management in secondary prevention on general clinical grounds and without specific reference to age.
